Prakt. lékáren. 2017; 13(2): 63-66 [Dermatol. praxi. 2016;10(4):178-180]
New classification of venoactive drugs
- I. dermatovenerologická klinika LF MU a FN u sv. Anny v Brně
Chronic venous disease (CVD) represents a major health problem, as its prevalence is high – up to 84% of population including
patients with clinical stage C0 (Vein Consult Programme, 2012). Venoactive drugs (VAD) are a basic conservative treatment of CVD.
New guidelines for the treatment of CVD were published in 2014. There are changes in classification of VAD based on their safety
and efficacy. Micronized purified flavonoid fraction (MPFF) is now the only VAD with grade 1B (a strong recommendation based
on moderate evidence). Rutosides, red wine leaves extracts, calcium dobesilate, horse chestnut seed extract and Ruscus extract
are all given grade 2B (weak recommendations based on moderate evidence). Nonmicronized diosmins and Gingko biloba are
given grade 2C (weak recommendations based on low quality evidence). MPFF is indicated in all stages of CVD and it is the only
VAD recommendated in the treatment of venous leg ulcers.
Keywords: chronic venous disease, venoactive drugs, classification, micronized purified flavonoid fraction
Received: February 3, 2016; Accepted: February 22, 2018; Prepublished online: April 17, 2018; Published: June 1, 2017 Show citation
References
- Rabe E, Guex JJ, Puskas A, et al. Epidemiology of chronic venous disorders in geographically diverse populations: results from the Vein Consult Program. Int Angiol 2012; 31(2): 105-115.
Go to PubMed... - Nicolaides A, Kakkos S, Eklof B, et al. Management of chronic venous disorders of the lower limbs. Guidelines according to scientific evidence. Int Angiol 2014; 33: 87-208. Go to PubMed...
- Ramelet AA, Boissean MR, Allegra C. Veno-active drugs in the management of chronic venous disease. An international consensus statement: Current medical position, prospective views and final resolution. Clin Hemorheol Microcirc 2005; 33: 309-319.
- Pascarella L, Lulic D, Penn AH, et al. Mechanisms in experimental venous valve failure and their modification by Daflon 500 mg. Eur J Vasc Endovasc Surg. 2008; 35: 102-110.
Go to original source... Go to PubMed... - Danziger N. Pathophysiology of pain in venous diseases, Phlebolymphology. 2008; 15(3) 107-114.
- Allaert FA. Meta-analysis of the impact of the principal venoactive drugs on malleolar venous edema, Int Angiol; 2012; 31(4): 310-315. Go to PubMed...
- Coleridge-Smith P, et al. Venous leg ulcer: A meta-analysis of adjunctive therapy with micronized purified flavonoid fraction. Eur J Vasc Endovasc Surg 2005; 30: 198-208. Go to original source... Go to PubMed...
- Ramelet AA. Clinical benefits of Daflon 500 mg in the most severe stages of chronic venous insufficiency. Angiology 2001; 52: 449-456. Go to original source... Go to PubMed...
- Roztočil K, Štvrtinová V, Strejček J. Efficacy of a 6-month treatment with Daflon 500 mg in patients with venous leg ulcers associated with CVI. Int Angiol 2003; 22: 1-8. Go to PubMed...